US OptionsDetailed Quotes
BCRX241220C7000
- 0.93
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.00High0.00Low
0.93Open0.93Pre Close0 Volume1.22K Open Interest7.00Strike Price0.00Turnover186.48%IV5.31%PremiumDec 20, 2024Expiry Date0.53Intrinsic Value100Multiplier5DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.6728Delta0.2209Gamma8.10Leverage Ratio-0.0632Theta0.0006Rho5.45Eff Leverage0.0032Vega
BioCryst Pharmaceuticals Stock Discussion
Sign in to post a comment
4
2
$BioCryst Pharmaceuticals (BCRX.US)$
BioCryst Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.81%)
BioCryst Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.81%)
Here are the levels to watch this week.
Larger Image: tradingview.com...
$BioCryst Pharmaceuticals (BCRX.US)$
Larger Image: tradingview.com...
$BioCryst Pharmaceuticals (BCRX.US)$
5
$BioCryst Pharmaceuticals (BCRX.US)$ BioCryst's ORLADEYO Reduces Hospital Visits and Emergency Care for Hereditary Angioedema Patients, Study Shows
Benzinga· 3 mins ago
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reduc...
Benzinga· 3 mins ago
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reduc...
$BioCryst Pharmaceuticals (BCRX.US)$ Reuters
Just
U.S. Government Awards BioCryst $69 Million Rapivab® (Peramivir Injection) Contract for Strategic National Stockpile
Just
U.S. Government Awards BioCryst $69 Million Rapivab® (Peramivir Injection) Contract for Strategic National Stockpile
The 2024 U.S. presidential race between former President Donald Trump and current Vice President Kamala Harris is still "incredibly close," according to the latest New York Times survey. As investors await the outcome of the November election, equity analysts are busy parsing through the candidates' pronouncements for clues on which stocks could benefit from their policies.
Jefferies analysts cited 10 possible policies that Tr...
Jefferies analysts cited 10 possible policies that Tr...
31
8
43
$BioCryst Pharmaceuticals (BCRX.US)$ Reuters · 1 min ago BioCryst Pharmaceuticals- Orladeyo® (Berotralstat) Approved in Peru
$BioCryst Pharmaceuticals (BCRX.US)$ Director ASELAGE STEVE purchased 2,500 shares of common stock on May 24, 2024 at an average price of $6.4 for a total value of $16,000.
1
$BioCryst Pharmaceuticals (BCRX.US)$ Benzinga· 1 min BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat
1
2
No comment yet
Youngman : okay what stocks should I keep an eye on in case this happenes?
Jaguar8 OP Youngman : Posted or tagged